mindmed

Home » mindmed

MindMed to Study Potential ‘Off Switch’ for LSD

Psychedelic medicine biotech firm MindMed has announced it has begun a study for a “neutralizer” technology that could shorten and stop the effects of an LSD trip during therapy, paving the way for an “emergency shut-off switch” for psychedelic-assisted therapy.

By |2021-02-20T01:14:27-08:00February 20, 2021|Articles & News, LSD, Studies|0 Comments

Can LSD Cure Our Pandemic Anxiety? MindMed is Spending Big to Find Out

MindMed is one of those companies. The Toronto-based firm is led by JR Rahn, a former Uber executive whose cocaine addiction led him to try psychedelics as a treatment—an experience he credits with saving his life. Rahn believes drugs like LSD could hold the key to helping the millions of people who have been driven to despair by the pandemic.

By |2021-02-18T22:16:23-08:00February 18, 2021|Articles & News, LSD, Studies|0 Comments

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

– MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.

By |2021-02-11T19:20:25-08:00February 11, 2021|Articles & News, DMT|0 Comments
Go to Top